Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study. - Soegiharto, R.; Alizadeh Aghdam, M.; Sørensen, J. A.; van Lindonk, E.; Bulut Demir, F.; Mohammad Porras, N.; Matsuo, Y.; Kiefer, L.; Knulst, A. C.; Maurer, M.; Ritchie, C.; Rudenko, M.; et al. (Allergy, 2025)